Clinical trials: Thrombotic Microangiopathies
Immune Thrombocytopenia (ITP)
The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
This is a randomized, double blinded, placebo-controlled phase Ib clinical trial in adult patients with immune thrombocytopenia. Cross-over treatment will be allowed during the study.
- Trial name
- NCT03951623
- Testing
- HMPL-523
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Hutchison Medipharma Limited
Purpura, Thrombocytopenic, Idiopathic
Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
OBJECTIVES: I. Determine the response rate and response duration to rituximab in patients with immune thrombocytopenic purpura. II. Evaluate the toxicity associated with this treatment regimen in these patients. III.
- Trial name
- NCT00005652
- Testing
- rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Primary Immune Thrombocytopenia
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study. The primary objective is to evaluate the safety and efficacy of SG301 SC Injection in participants with ITP, while the secondary…
- Trial name
- NCT07710248
- Testing
- low dose group, high dose group
- Where
- 22 sites in China
- Volunteers
- 60 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Immune Thrombocytopenic Purpura
Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytopenia
The purpose of this study is to determine whether All-trans retinoic acid (ATRA) are effective in the treatment of refractory idiopathic thrombocytopenic purpura (RITP).
- Trial name
- ITP (NCT01668615)
- Testing
- all-trans-retinoid acid
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Suzhou Medical College
Immune Thrombocytopenic Purpura
Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10
The purpose of this study is to evaluate the efficacy, tolerability and safety of IgPro10 in the treatment of patients with chronic immune thrombocytopenic purpura (ITP).
- Trial name
- NCT00168038
- Testing
- Immunoglobulin Intravenous (Human)
- Where
- 17 sites in Germany, Italy and 4 more
- Volunteers
- 58 people
- Sponsor
- CSL Behring
Purpura, Thrombocytopaenic, Idiopathic
A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
A open-label, multi-center 2-year safety study to ascertain the baseline levels of bone marrow fibers in previously treated adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and to evaluate the long-term…
- Trial name
- NCT01098487
- Testing
- Eltrombopag olamine
- Where
- 34 sites in United States, Czechia and 9 more
- Volunteers
- 167 people
- Sponsor
- GlaxoSmithKline
Immune Thrombocytopenia
The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Single-arm, open-lable, multicentre study to compare the efficacy and safety of atorvastatin, acetylcysteine plus danazol with danazol monotherapy in patients with corticosteroidresistant/relapsed ITP.
- Trial name
- NCT03460808
- Testing
- atorvastatin, Acetylcysteine, Danazol
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Thrombotic Microangiopathy
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA.
- Trial name
- NCT04557735
- Testing
- Ravulizumab, Best Supportive Care
- Where
- 26 sites in United States, Israel and 5 more
- Volunteers
- 41 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
ITP, Immune Thrombocytopenia
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
Evaluate patient characteristics, treatment patterns, clinical outcomes and safety of fostamatinib as second-line therapy in real-world clinical practice, for the treatment of ITP in adult patients who have an insufficient…
- Trial name
- NCT04904276
- Testing
- Fostamatinib
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Rigel Pharmaceuticals
Immune Thrombocytopenia
Use of Vitamin D as An Adjuvant Treatment in Children With Chronic Idiopathic Thrombocytopenic Purpura
Immune thrombocytopenia is an autoimmune disease in which platelets are targeted by the host immune system. Platelet depletion occurs when autoantibodies targeting glycoproteins (αIIb-β3 and GPIb) found on the surface of…
- Trial name
- MansouraU (NCT06073925)
- Testing
- VIT D
- Volunteers
- 30 people
- Sponsor
- Mansoura University
Atypical Hemolytic Uremic Syndrome, aHUS
Observational Study of Elizaria® in aHUS Patients
It is a multicenter observational non-comparative study of the efficacy and safety of long-term pathogenetic Elizaria® therapy in patients with atypical Hemolytic Uremic Syndrome
- Trial name
- NCT04749810
- Testing
- Elizaria®
- Where
- 8 sites in Russia
- Volunteers
- 50 people
- Sponsor
- AO GENERIUM
Nonneoplastic Condition
Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura
RATIONALE: Drugs, such as prednisone and dexamethasone, may change the immune system and be an effective treatment for primary immune thrombocytopenic purpura.
- Trial name
- ITP0207 (NCT00657410)
- Testing
- dexamethasone, prednisone, quality-of-life assessment
- Where
- 42 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Purpura, Thrombocytopenic, Idiopathic
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
The purpose of this study is to determine whether Fostamatinib Disodium is safe and effective in the treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP).
- Trial name
- NCT00706342
- Testing
- Fostamatinib Disodium / R935788
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Rigel Pharmaceuticals
Acquired Thrombotic Thrombocytopenic Purpura
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
This study was a Phase II, single-blind, randomized, placebo-controlled trial to determine whether anti-vWF Nanobody is safe and effective as adjunctive treatment in patients with aTTP.
- Trial name
- TITAN (NCT01151423)
- Testing
- Caplacizumab
- Where
- 51 sites in United States, Australia and 11 more
- Volunteers
- 75 people
- Sponsor
- Ablynx, a Sanofi company
Acquired Thrombotic Thrombocytopenic Purpura
A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)
This is a multicenter, randomized, double-blind, parallel, placebo-controlled phase II clinical study. It is planned to recruit 74 patients with acquired thrombotic thrombocytopenic purpura (TTP).
- Trial name
- NCT04021173
- Testing
- Anfibatide
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Lee's Pharmaceutical Limited
Immune Thrombocytopenia (ITP), ITP
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
- Conditions
- Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal
- Trial name
- NCT07043946
- Testing
- Budoprutug
- Where
- 20 sites in Bulgaria, Greece and 3 more
- Volunteers
- 24 people
- Sponsor
- Climb Bio, Inc.
Immune Thrombocytopenia
An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
The primary objective of this study was to assess the long-term safety of lusutrombopag in the treatment of adults with relapsed persistent or chronic ITP with or without prior splenectomy.
- Trial name
- NCT01129024
- Testing
- Lusutrombopag
- Where
- 19 sites in United States
- Volunteers
- 19 people
- Sponsor
- Shionogi
Hairy Cell Leukemia
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
This study is being conducted to satisfy a post-marketing requirement (PMR) to provide evidence characterizing 1) the safety of moxetumomab pasudotox-tdfk in patients who are 65 years of age and older and/or 2) the safety of…
- Trial name
- PROXY (NCT04125290)
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Immune Thrombocytopenia
Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia
The investigators will attempt to further increase the cure rate of ITP with medical therapy by providing maintenance therapy with Mycophenolate mofetil (MMF) to persistent/chronic ITP patients after treating them with induction…
- Trial name
- NCT02649504
- Testing
- Rituximab, Dexamethasone, Mycophenolate mofetil
- Sponsor
- Weill Medical College of Cornell University
Primary Immune Thrombocytopenia (ITP)
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)
This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in patients with primary ITP.
- Trial name
- ADVANCE2 (NCT04274452)
- Testing
- efgartigimod
- Sponsor
- argenx